StemRIM Inc. (4599) AI Stock Analysis

• Market Cap: ¥18.55B
• Dividend Yield: N/A
• Average Volume (3M): 122.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.02
• Revenue Growth: N/A
• EPS Growth: 11.34%
• Country: JP
• Employees: 44
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -6.42
• Shares Outstanding: 62,681,200
• 10 Day Avg. Volume: 118,910
• 30 Day Avg. Volume: 122,863
• PEG Ratio: 1.85
• Price to Book (P/B): 2.69
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.50
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -30.8
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: ¥286.00 ▲(12.16% Upside)
• Action: Reiterated Date: 12/30/25
• Date: Action: Reiterated 12/30/25

The score is mainly weighed down by weak recent financial performance (no revenue, large losses, and ongoing cash burn) and an unfavorable valuation signal (negative P/E with no dividend). Technicals are also soft, with the stock below key longer-term moving averages and negative MACD.

Positive Factors

Conservative balance sheet / very low debt

A near-zero debt profile reduces refinancing and interest-rate risks, preserving financial optionality for a biotech firm that may need to raise capital episodically. This structural conservatism lengthens runway and supports strategic flexibility over the next several quarters.

Proven ability to generate positive cash and profit in 2023

A demonstrated episode of strong cash generation and profitability (2023) shows the business model can deliver commercial or partner-derived revenue under the right conditions. That track record reduces absolute execution risk and indicates the platform can monetize assets when catalysts align.

Lean organizational footprint (small employee base)

A small, focused workforce supports lower fixed overhead and greater capital efficiency—advantages for a cash-constrained biotech. This structural lean setup helps preserve cash, accelerates decision cycles, and allows targeted R&D spend without large SG&A drag.

Negative Factors

Zero revenue in 2024–2025 with large operating and net losses

Sustained absence of revenue removes margin buffers and forces reliance on financing; large recurring operating and net losses erode capital and make it harder to self-fund trials or commercialization. This structural revenue gap materially raises execution and funding risk.

Inconsistent cash generation; sharp swing to recent cash burn

Volatile cash flow history and a sharp swing from 2023 inflows to 2024–2025 outflows indicate unstable funding dynamics. Persistent negative operating and free cash flow increases dilution risk and dependency on capital markets or partners to sustain operations long term.

Equity erosion and negative returns on equity in recent years

Declining shareholders' equity and repeated negative ROE signal value dilution and impaired capital efficiency. If losses persist, further equity erosion or dilutive financings are likely, undermining long-term shareholder returns and limiting the company’s strategic options.

StemRIM Inc. Business Overview & Revenue Model

Company Description

StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.

StemRIM Inc. Financial Statement Overview

Summary

Financials are pressured by zero revenue in 2024–2025 with very large operating/net losses and significant cash burn, despite a low-debt balance sheet. While the company has shown occasional strong years (notably 2023), the recent trend points to weakened sustainability and higher financing risk.

Income Statement

Profitability has been highly volatile and recently weak. After a profitable 2020 and 2023 (including a sharp revenue jump in 2023), the company reported zero revenue in 2024 and 2025 with very large operating and net losses, indicating a heavy cost base without offsetting commercial/partner income. Margins are not meaningful in the last two years due to the lack of revenue, and the earnings trajectory has turned decisively negative again.

Balance Sheet

The balance sheet is conservatively financed with essentially no debt across the period, which reduces financial risk. However, equity has declined meaningfully from 2021 to 2025, consistent with ongoing losses and cash burn. Returns on equity are negative in 2022, 2024, and 2025, reflecting value dilution risk if losses persist.

Cash Flow

Cash generation is inconsistent: operating and free cash flow were positive in 2020 and strongly positive in 2023, but turned materially negative in 2021, 2022, 2024, and 2025. The last two years show significant cash burn, broadly tracking net losses, which increases dependence on existing cash reserves or future funding. The sharp swing from 2023 inflows to 2024–2025 outflows highlights elevated volatility in funding/cash timing.

Breakdown	Jul 2025	Jul 2024	Jul 2023	Jul 2022	Jul 2021
Income Statement
Total Revenue	0.00	0.00	2.35B	22.98M	1.40B
Gross Profit	-49.50M	-44.35M	2.30B	0.00	0.00
EBITDA	-1.92B	-2.03B	190.18M	-1.93B	-550.13M
Net Income	-1.93B	-2.02B	168.35M	-1.95B	-582.45M
Balance Sheet
Total Assets	7.52B	9.09B	10.72B	9.61B	10.93B
Cash, Cash Equivalents and Short-Term Investments	6.99B	8.41B	10.22B	8.88B	10.17B
Total Debt	0.00	0.00	531.00K	3.67M	6.73M
Total Liabilities	210.27M	194.06M	348.51M	207.74M	231.10M
Stockholders Equity	7.31B	8.89B	10.37B	9.40B	10.70B
Cash Flow
Free Cash Flow	-1.46B	-1.88B	1.14B	-1.40B	-608.70M
Operating Cash Flow	-1.41B	-1.88B	1.14B	-1.40B	-519.65M
Investing Cash Flow	-42.50M	-4.78M	-344.00K	-330.00K	-92.72M
Financing Cash Flow	41.25M	78.97M	202.60M	112.86M	109.32M

StemRIM Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 255.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4599, the sentiment is Neutral. The current price of 255 is below the 20-day moving average (MA) of 297.55, below the 50-day MA of 293.98, and below the 200-day MA of 295.09, indicating a neutral trend. The MACD of 2.23 indicates Positive momentum. The RSI at 49.54 is Neutral, neither overbought nor oversold. The STOCH value of 57.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4599.

StemRIM Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4880	57 Neutral	¥7.96B	59.41	―	1.24%	-14.78%	-95.53%
4978	56 Neutral	¥16.02B	120.78	―	―	1.24%	-33.41%
7774	54 Neutral	¥24.81B	-34.16	―	―	-5.65%	-469.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4593	50 Neutral	¥53.60B	-13.30	―	―	-82.33%	47.73%
7776	49 Neutral	¥12.00B	-8.14	―	―	-42.49%	-2.37%
4599	43 Neutral	¥18.55B	-11.30	―	―	―	11.34%

StemRIM Inc. Corporate Events

StemRIM Unveils Midterm FY2026 Results and R&D Progress in Regenerative Medicine

StemRIM Inc. released presentation materials outlining its financial results for the six months ended January 31, 2026 and provided an overview of management indicators, financial summaries, and key business highlights. The update also detailed progress in research and development, advances in its regeneration-inducing medicine platform, IP strategy, and business development activities, indicating continued execution of its growth and innovation plans in regenerative therapeutics.

The most recent analyst rating on (JP:4599) stock is a Hold with a Yen299.00 price target. To see the full list of analyst forecasts on StemRIM Inc. stock, see the JP:4599 Stock Forecast page.

StemRIM narrows interim loss as it ramps R&D on regenerative drug pipeline

StemRIM reported no operating revenue and a net loss of ¥928 million for the six months to Jan. 31, 2026, narrowing slightly from the previous year’s ¥1,048 million loss as basic loss per share improved to ¥14.91. Total assets fell to ¥6,812 million and the equity ratio declined to 74.6%, while the company again declared no interim dividend and has withheld a full-year earnings forecast due to the volatility of milestone income.

Management said it will continue advancing its flagship Regeneration-Inducing Medicine candidate Redasemtide and subsequent pipeline assets toward clinical development and out-licensing, with forecast cash R&D spending of ¥1.3–1.7 billion and SG&A of ¥230–310 million in the current fiscal year. StemRIM noted potential upfront and milestone payments from new and existing partnerships but emphasized it has already secured sufficient funding to support its research and development activities through 2028, offering some visibility for investors despite ongoing losses and uncertain revenue timing.

The most recent analyst rating on (JP:4599) stock is a Hold with a Yen280.00 price target. To see the full list of analyst forecasts on StemRIM Inc. stock, see the JP:4599 Stock Forecast page.

StemRIM Wins Key Patent on Gene Therapy SR-GT1 for Dystrophic Epidermolysis Bullosa

StemRIM Inc. announced that a Japanese patent has been granted for a stem cell gene therapy technology, SR-GT1, designed to provide a curative treatment for dystrophic epidermolysis bullosa, a severe hereditary skin disorder caused by defects in type VII collagen. The patent covers the therapeutic approach of administering genetically corrected autologous mesenchymal stem cells into patients’ blisters, supporting long-term collagen production to restore skin integrity.

The newly secured intellectual property strengthens StemRIM’s technological base for treating recessive dystrophic epidermolysis bullosa and complements its existing portfolio developed with Osaka University. SR-GT1 is being produced as an investigational drug with support from Japan’s AMED, and preparations for an early transition to a physician-led clinical trial are progressing, though the company expects no material impact on earnings for the current fiscal year.

The most recent analyst rating on (JP:4599) stock is a Hold with a Yen302.00 price target. To see the full list of analyst forecasts on StemRIM Inc. stock, see the JP:4599 Stock Forecast page.

StemRIM Wins Canadian Patent for Redasemtide Use in Cartilage Disorders

StemRIM Inc. has secured a forthcoming Canadian patent covering the use of its peptide drug candidate Redasemtide, an HMGB1 fragment peptide, as a therapeutic agent for a broad spectrum of cartilage disorders including osteoarthritis, meniscal damage, and certain forms of arthritis. The patent expands potential indications for Redasemtide in Canada and supports the company’s strategy to develop an intravenously administered, low-burden regenerative treatment that mobilizes mesenchymal stem cells to sites of cartilage injury, although StemRIM expects no material impact on its financial results for the fiscal year ending July 31, 2026.

By reinforcing Redasemtide’s intellectual property position in a key market, the move underpins StemRIM’s efforts to establish its regeneration-inducing platform in orthopedic and joint disease segments where current therapies are often limited and conditions are typically chronic and progressive. The additional protection may enhance the company’s competitive standing in cartilage repair therapies and provide long-term optionality for partnerships or future commercialization, while short-term financial effects remain minimal.

The most recent analyst rating on (JP:4599) stock is a Hold with a Yen281.00 price target. To see the full list of analyst forecasts on StemRIM Inc. stock, see the JP:4599 Stock Forecast page.

StemRIM Completes Global Phase 2b Enrollment for Stroke Drug Redasemtide

StemRIM Inc. announced that partner Shionogi & Co. has completed patient enrollment in a global Phase 2b clinical trial of Redasemtide (S‑005151), a peptide drug derived from StemRIM’s “Regeneration-Inducing Medicine” platform, for adults with acute ischemic stroke treated within 25 hours of onset. The trial, conducted across 18 countries including Japan, the U.S. and European states, is evaluating the efficacy and safety of Redasemtide versus placebo—with or without endovascular recanalization—using the 90-day modified Rankin Scale as the primary endpoint; the company noted the program is progressing as planned and is not expected to affect full-year earnings for the fiscal year ending July 2026, underscoring steady advancement of its lead regenerative therapeutic without near-term financial disruption.